Company intelligence / Profile preview

Science Impact

Ness Ziona, Central District, Israelimpact.pub ↗

Ownership: Private
Development stage: Other

Overview

ImPact Biotech’s lead program, Padeliporfin VTP, is in a pivotal Phase 3 trial for low-grade upper tract urothelial carcinoma with enrollment expected to complete by Q1 2025. Earlier-stage studies are ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma, and non-small cell lung cancer. The platform has shown promising safety and efficacy profiles in prior research on prostate cancer and received FDA orphan drug designation for pancreatic cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeDevice (drug-device combination)Photodynamic therapy
Industry: Biotech

Partnerships

Weizmann Institute of ScienceMemorial Sloan Kettering Cancer CenterEuropean Innovation Council Accelerator Program investment/grant

Beyond the preview

Go deeper on Science Impact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Science Impact.

Explore the full profile